Personal details

Name
Associate Professor Peter Molenaar
Position(s)
Associate Professor
Faculty of Health,
School - Biomedical Sciences
IHBI Membership
Institute of Health Biomedical Innovation (IHBI),
IHBI Health Projects,
IHBI Biomedical Sciences - CDA
Discipline *
Pharmacology and Pharmaceutical Sciences, Other Biological Sciences
Phone
+61 439 776 409
Fax
Prince Charles Hospital
Email
Location
View location details (QUT staff and student access only)
Identifiers and profiles
ORCID iD
Qualifications

PhD (The University of Melbourne)

Professional memberships
and associations
  • Australian Society for Clinical and Experimental Pharmacology and Toxicology(ASCEPT)
  • British Pharmacological Society
Keywords

Beta-adrenoceptors, G-protein coupled receptors, Human Heart Research, in vitro human heart research

* Field of Research code, Australian and New Zealand Standard Research Classification (ANZSRC), 2008

Biography

Research theme: Health
Research discipline: Pharmacy
Research areas
Investigation of the molecular properties and physiological significance of different ‘states’ of the (1-adrenoceptor: (1-Adrenoceptors are proteins that exist in human heart which mediate the cardiostimulant effects of noradrenaline. Some (-blockers, such as (-)-CGP 12177 not only block the receptor but also stimulate it. To accommodate this finding we have proposed that noradrenaline and cardiostimulant (-blockers bind differently to the (1-adrenoceptor.
We are investigating: a. the specific features of the (1-adrenoceptor that are critical for activation of the receptor by (-blockers; b. whether activation of the receptor by (-blockers such as (-)-CGP 12177 causes progression of heart failure in an animal model of heart failure and; c. the chemical features of (-blockers that cause the receptor to be activated and not blocked. These studies are likely to lead to the improved design of (-blockers for clinical use.
The genetic basis of (-blocker responsiveness in human heart failure: The clinical effect of (-blockers in human heart failure is quite variable. Some patients show marked improvement in heart function whilst others show marginal or no improvement. In patients with non-ischemic cardiomyopathy treated with carvedilol we found that the Arg389Gly-(1-adrenoceptor polymorphism predicts improvement in left ventricular ejection fraction.
Investigation of phosphodiesterase enzymes that are responsible for the metabolism of cyclic AMP accumulated by activation of (1- and (2-adrenoceptors in human ventricle: In human heart phosphodisterase enzymes metabolize the cyclic AMP that is increased in response to activation of (-adrenoceptors. These enzymes can be considered to have a protective role against the harmful effects of excessive (-adrenoceptor activation. We are currently investigating the phosphodiesterases that are responsible for metabolism of cyclic AMP raised by activation of (1- and (2-adrenoceptors in human ventricle from patients with end-stage heart failure.
Areas of expertise:

  • Human heart research
  • G-protein coupled receptors
  • Beta-adrenoceptors
  • Polymorphisms
This information has been contributed by Associate Professor Peter Molenaar.

Teaching

Teaching discipline: Pharmacy

This information has been contributed by Associate Professor Peter Molenaar.

Publications

For publications by this staff member, visit QUT ePrints, the University's research repository.